Treatment with eflornithine led to clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) for patients with recurrent grade 3 IDH-mutant astrocytoma, an ...
Copyright held by the owner/author(s).
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Major Finding: A dual function supracluster was engineered to increase radiosensitivity and antitumor immunity. Concept: Gold supraclusters carrying siRNA against LGALS1 (galectin-1) reshaped the ...
Search for other works by this author on: ...
Merck announced today that pembrolizumab (Keytruda) injected subcutaneously is not inferior to intravenous (IV) dosing, currently the drug’s only approved route of administration. In the phase III ...
Major Finding: Antitumor T cells are recruited to intracranial metastases through ICAM-1 + peritumoral venous vessels (PVV). Concept: PVVs mediate T-cell recruitment and motility, which can be ...
Clin Cancer Res (2024) 30 (21_Supplement): A045.
Bristol Myers Squibb (BMS) faces a $6.7 billion lawsuit alleging that the company purposely delayed approval of Celgene-developed drugs to avoid paying Celgene shareholders owning contingent value ...
Search for other works by this author on: ...
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2Department of Medicine, Weill Cornell Medical College, New York, New York. *Corresponding Author: Claire F.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback